- Home
- TIL vs NBTX Comparison
TIL vs NBTX Comparison
Compare TIL & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- NBTX
- Stock Information
- Founded
- TIL 2018
- NBTX 2003
- Country
- TIL United States
- NBTX France
- Employees
- TIL N/A
- NBTX N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- TIL Health Care
- NBTX Health Care
- Exchange
- TIL Nasdaq
- NBTX Nasdaq
- Market Cap
- TIL 171.7M
- NBTX 178.7M
- IPO Year
- TIL 2021
- NBTX 2020
- Fundamental
- Price
- TIL $14.48
- NBTX $3.34
- Analyst Decision
- TIL Buy
- NBTX Strong Buy
- Analyst Count
- TIL 5
- NBTX 1
- Target Price
- TIL $114.00
- NBTX $8.00
- AVG Volume (30 Days)
- TIL 178.2K
- NBTX 11.0K
- Earning Date
- TIL 05-13-2025
- NBTX 04-02-2025
- Dividend Yield
- TIL N/A
- NBTX N/A
- EPS Growth
- TIL N/A
- NBTX N/A
- EPS
- TIL N/A
- NBTX N/A
- Revenue
- TIL N/A
- NBTX N/A
- Revenue This Year
- TIL N/A
- NBTX N/A
- Revenue Next Year
- TIL N/A
- NBTX $221.06
- P/E Ratio
- TIL N/A
- NBTX N/A
- Revenue Growth
- TIL N/A
- NBTX N/A
- 52 Week Low
- TIL $9.62
- NBTX $2.76
- 52 Week High
- TIL $92.00
- NBTX $7.51
- Technical
- Relative Strength Index (RSI)
- TIL 46.45
- NBTX 50.86
- Support Level
- TIL $10.80
- NBTX $3.15
- Resistance Level
- TIL $13.52
- NBTX $3.59
- Average True Range (ATR)
- TIL 2.23
- NBTX 0.14
- MACD
- TIL -0.17
- NBTX 0.02
- Stochastic Oscillator
- TIL 27.06
- NBTX 47.25
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.